CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk
CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk
The aim of the study is to investigate the longterm impact on cardiovascular morbidity, mortality and renal function of treatment with linagliptin in a selected population of patients with Type 2 diabetes mellitus (T2DM) and to compare outcomes against placebo, on a background of standard of care.
Inclusion criteria:
Exclusion criteria:
Fort Lauderdale, Florida 33312, United States
Albuquerque, New Mexico 87106, United States
Caba, C1419GEP, Argentina
Ciudad Autonoma Buenos Aires, C1056ABJ, Argentina
Ciudad Autonoma Buenos Aires, C1119ACN, Argentina
Ciudad Autonoma Buenos Aires, C1181ACH, Argentina
Ciudad Autonoma Buenos Aires, C1425AGC, Argentina
Ciudad Autonoma Buenos Aires, C1425DES, Argentina
Ciudad Autonoma Buenos Aires, C1428ART, Argentina
Ciudad Autonoma Buenos Aires, C1430CKE, Argentina
Ciudad Autonoma de Bs As, C1120AAC, Argentina
Praha 4 - Krc, 140 59, Czechia
Aichi, Nagoya, 462-0825, Japan
Chiba, Matsudo, 271-0077, Japan
Fukuoka, Iizuka, 820-8505, Japan
Fukuoka, Kitakyushu, 800-0295, Japan
Hyogo, Kawanishi, 666-0125, Japan
Kanagawa, Kawasaki, 210-0852, Japan
Nagano, Nagano, 380-8582, Japan
V. N. Gaia, 4434-502, Portugal
Novosibirsk, 630117, Russia
Taoyuan County, 333, Taiwan
Ternopli, 46002, Ukraine